Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

V-101 demonstrates neurogenesis in rodent models
March 2019
SHARING OPTIONS:

SOUTH SAN FRANCISCO, Calif.—Recent nonclinical studies have shown that AV-101 (4-chlorokynurenine) can promote hippocampal neurogenesis (the formation of new neurons), VistaGen Therapeutics announced recently. The studies were conducted on rodents, who received oral daily dosing of AV-101 for 14-16 days and showed increased neurogenesis, as monitored by an increase in the number of cells with Ki67, a marker of dividing cells. The rats were scored by scientists blinded to the treatment groups.
 
“The development of new neurons is a vital part of our mental growth during adulthood, and the exciting results of these nonclinical studies highlight AV-101’s potential to promote adult hippocampal neurogenesis. We believe these results are potentially far-reaching, especially given that enhanced hippocampal cell proliferation provides protection against stress-related psychiatric disorders, including depression,” said Shawn Singh, CEO of VistaGen.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.